Although progression-free survival also appeared reduced in patients with anti-PL7+, this did not reach statistical significance, but graphical modelling of %FVC over time did demonstrate a later more evident deterioration in FVC in this group compared with that for other antibodies from 6 months onwards.
← all excerpts
Antibody predictors of mortality and lung function trends in myositis spectrum interstitial lung disease.
1
—
—